MannKind withdraws CEO job offer to DeSisto; Illumina launches $100M 'holy grail' project;

@FierceBiotech: The Bradner factor: Roche bags a BET inhibitor in $535M Tensha buyout. Article | Follow @FierceBiotech

@JohnCFierce: Shire finally gets it done, bagging Baxalta in $32B buyout. News | Follow @JohnCFierce

> Duane DeSisto won't be joining MannKind ($MNKD) as its new CEO after all. The company says it withdrew the job offer after DeSisto's former company, Insulet, said the position would violate a noncompete in effect until September. MannKind has been struggling to deal with Sanofi's ($SNY) decision to dump its big partnership for the inhaled insulin Afrezza, which has experienced a dismal reception. Release

> Cidara Therapeutics ($CDRA) says it successfully wrapped up a Phase I ascending dose study for its antifungal drug candidate, CD101 IV, in healthy subjects. Release

> Illumina ($ILMN) is targeting liquid biopsies with its latest endeavor, rounding up some high-profile investors to launch a spinout called Grail with a $100 million Series A round. News

Medical Device News

@FierceMedDev: ICYMI: Israeli startup raises $10M to back transcatheter aortic valve stenosis treatment. Article | Follow @FierceMedDev

@EmilyWFierce: Who's on board with Twitter's 10,000 character limit? Pharma brand managers. FiercePharmaMarketing story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Startup raises $14M to commercialize its filter to prevent blood clots during hospitalization. Article | Follow @VarunSaxena2

> Illumina focuses on 'holy grail market opportunity' with liquid biopsy spinoff. Article

> Thermo Fisher to buy Affymetrix for $1.3B to beef up in genetic analysis. Report

> JPM: Med tech 'innovation studio' debuts thanks to $15M investment from American Medical Association. Story

Pharma News

@FiercePharma: Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Waiting for flight/playing "guess where these guys work based on overheard description of latest clinical trial failure." | Follow @CarlyHFierce

> Single-minded Shire finally pins down Baxalta with $32B deal. Article

Animal Health News

> USDA shifts attention to diagnostics to curb deadly pig virus. More

> China Animal Healthcare creates embarrassment for stakeholder Lilly. Report

> Startup AGL launches dog-collar sensor for remote tracking of chronic illnesses. Story

> Researchers ID link between fish-flavored cat food and thyroid disease. Item

> Zoetis offloads manufacturing sites as CFO embraces activist investors. Article

Biotech IT News

> Roche leads $175M investment in oncology software player Flatiron. News

> MC10 pitches data-gathering wearable patch at research community. Report

> Pfizer taps Adaptive to add NGS, bioinformatics skills to immuno-oncology drive. Story

> Michael J. Fox Foundation signs up for wearable-enabled Phase III trial project. Item

> Vertex inks deal to add Genomics' database, algorithms to drug discovery toolkit. Article

Pharma Marketing News

> Who's on board with Twitter's 10,000 character limit? Pharma brand managers. Story

> Will GSK's no-speaker-fee system work? Execs say yes; critics, not so much. More

> Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. Article

> Shire to take on hemophilia marketing with long-sought Baxalta buy. Item